Emtricitabine and tenofovir disoproxil Doc Generici: detailed information

Patient Information Leaflet

EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics

200 mg/245 mg film-coated tablets
Generic medicine
Please read all of this leaflet carefully before you start taking this medicine, as it contains important
information for you.

Keep this leaflet. You may need to read it again.
If you have any questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not give it to other people, even if their symptoms are the same as yours, as it may be harmful.
If you experience any side effects, including those not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Contents of this leaflet:

What EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics is and what it is used for
What you need to know before taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics
How to take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics
Possible side effects
How to store EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics
Contents of the pack and other information

1. What EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici is and what it is used for

EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici contains two active substances,
emtricitabine and tenofovir disoproxil succinate. Both active substances are antiretroviral medicines used for the treatment of HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor and tenofovir is a nucleotide reverse transcriptase inhibitor. However, they are generically known as NRTIs and work by interfering with the normal activity of an enzyme (reverse transcriptase) that is essential for the virus to replicate.

EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici is used to treat human immunodeficiency virus-1 (HIV-1) infection in adults.
It is also used to treat HIV in adolescents aged 12 to less than 18 years weighing at least 35 kg who have previously been treated with other HIV medicines that are no longer effective or have caused undesirable effects.
EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici must always be used in combination with other medicines for the treatment of HIV infection.
EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici may be administered as a substitute for emtricitabine and tenofovir disoproxil taken separately at the same doses.

People infected with HIV can still transmit the virus even while taking this medicine, although the risk is reduced by effective antiviral therapy. Discuss with your doctor the necessary precautions to avoid transmitting the infection to others.
This medicine is not a cure for HIV infection. While taking EMTRICITABINE AND
TENOFOVIR DISOPROXIL DOC Generici, you may still develop infections or other illnesses associated with HIV infection.

EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici is also used to reduce the risk of acquiring HIV-1 infection in adults, when used as a daily treatment, along with safe sexual practices: See section 2 for a list of precautions to prevent HIV infection.

2. What you should know before taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC

Generics
Do not take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to treat HIV or
to reduce the risk of getting HIV

if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil fumarate, or any of the other ingredients of this medicine (listed in section 6). If this applies to you, inform your doctor immediately. Before taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to reduce the risk of getting HIV: EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics can only help reduce the risk of getting HIV before you become infected.
To start taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to reduce the risk of getting HIV, you must be HIV-negative. You must undergo an HIV test to ensure you do not already have an HIV infection. Do not take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to reduce the risk unless it has been confirmed that you are HIV-negative. People who have HIV must take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics in combination with other medicines.
Many HIV tests may not detect a recent infection. If you develop flu-like illness, it could mean you have recently been infected with HIV. Symptoms of HIV infection may include:
fatigue
fever
joint or muscle pain
headache
vomiting or diarrhoea
rash
night sweats
swollen lymph nodes in the neck or groin
Tell your doctor if you develop flu-like symptoms within the month before starting EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics or at any time while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics.
Warnings and precautions
While taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to reduce the risk of getting HIV:
Take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics every day to reduce the risk, not only when you think you may have been exposed to HIV infection. Do not miss any doses of EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics and do not stop taking it. Missing doses may increase your risk of acquiring HIV infection.
Get tested for HIV regularly.
If you think you may have been infected with HIV, inform your doctor immediately. Your doctor may perform additional tests to confirm that you are still HIV-negative.
Simply taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics may not prevent you from getting HIV.
o Always practice safe sex. Use condoms to reduce contact with semen, vaginal fluid, or blood.
o Do not share personal items that may have blood or body fluids on them, such as toothbrushes or razors.
o Do not share or reuse needles or other injection or medication administration equipment.
o Get tested for other sexually transmitted infections such as syphilis and gonorrhoea. These infections increase the risk of HIV infection. Talk to your doctor if you have further questions about how to avoid getting or spreading HIV.

While taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to
treat HIV or to reduce the risk of getting HIV:

EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics may affect your kidneys. Before and during treatment, your doctor may prescribe blood tests to monitor kidney function. Inform your doctor if you have had kidney disease or if blood tests have shown kidney problems. EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics should not be given to adolescents with kidney problems. If you have kidney problems, your doctor may advise you to stop taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics or, if you already have HIV, to take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics less frequently. EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics is not recommended if you have severe kidney disease or are on dialysis.

Bone problems (sometimes resulting in fractures) may also occur due to damage to the renal tubular cells (see section 4, Possible side effects).

Inform your doctor if you have previously had liver problems, including hepatitis. HIV-infected patients with existing liver problems (including chronic hepatitis B or C) who are treated with antiretrovirals have a higher risk of serious liver complications, which may be fatal. If you have hepatitis B or C, your doctor will carefully evaluate the most appropriate treatment regimen for you.
Get tested for hepatitis B virus (HBV) infection before starting EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics. If you have an HBV infection, stopping EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics may lead to serious liver problems, whether or not you have HIV. It is important that you do not stop taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics without consulting your doctor: see section 3, Do not stop treatment with EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics.
Inform your doctor if you are over 65 years old. EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics has not been studied in patients over 65 years of age.
Inform your doctor if you are lactose intolerant (see EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics contains lactose later in this section).

Children and adolescents

EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics is not indicated in children under 12 years of age.

Other medicines and EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics
Do not take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics if you are already taking
other medicines containing the components of EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC
Generics (emtricitabine and tenofovir disoproxil) or any other antiviral medicine containing tenofovir
alafenamide, lamivudine, or adefovir dipivoxil.
Taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics with other medicines
that may damage the kidneys: it is particularly important to inform your doctor if you are taking
any of the following medicines, including

aminoglycosides (for bacterial infection)
amphotericin B (for fungal infection)
foscarnet (for viral infection)
ganciclovir (for viral infection)
pentamidine (for infections)
vancomycin (for bacterial infection)
interleukin-2 (for cancer treatment)
cidofovir (for viral infection)
non-steroidal anti-inflammatory drugs (NSAIDs, used to relieve bone or muscle pain).

If you are taking another antiviral medicine called a protease inhibitor for the treatment of HIV, your doctor
may prescribe blood tests to more closely monitor your kidney function.
It is also important to inform your doctor if you are taking ledipasvir/sofosbuvir or sofosbuvir/velpatasvir for
the treatment of hepatitis C infection.
Taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics with medicines containing
didanosine (for the treatment of HIV infection):
Taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics with other antiviral medicines
containing didanosine may increase the level of didanosine in the blood and may reduce CD4 cell count. When medicines containing tenofovir disoproxil and didanosine have been taken together, rare cases of pancreatitis and lactic acidosis (excess lactic acid in the blood) have been reported, which sometimes resulted in death. Your doctor must carefully consider whether to treat you with tenofovir and didanosine in combination.
Inform your doctor if you are taking any of these medicines. Inform your doctor or pharmacist
if you are taking, have recently taken, or might take any other medicines.
EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics with food and drink
EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics should be taken with food whenever possible.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, are planning to become pregnant, or are breastfeeding, ask your doctor or pharmacist for advice before taking this medicine.

Although there are limited clinical data on the use of EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics in pregnant women, it is generally not used unless absolutely necessary.
If you are a woman of childbearing potential during treatment with EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics, you must use an effective contraceptive method to avoid pregnancy.
If you are pregnant or planning a pregnancy, ask your doctor about the potential benefits and risks of treatment with EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics for you and your baby. If you have already taken EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics during pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor your baby's development. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV infection has outweighed the risk of side effects.
Do not breastfeed while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics. This is because the active substance of this medicine is excreted in breast milk.
If you are an HIV-infected woman, you are advised not to breastfeed in order to avoid transmitting the HIV virus to the newborn through breast milk.

Driving and using machines
EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics may cause dizziness. If dizziness occurs while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics, do not drive and do not use tools or machines.
EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics contains lactose
Inform your doctor if you are lactose intolerant or have other sugar intolerances.

3. How to take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics

Take this medicine exactly as directed by your doctor. If you have any doubts, consult your doctor or pharmacist.

The recommended dose of EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics for
treating HIV is:

Adults: one tablet daily, preferably taken with food.
Adolescents aged 12 to less than 18 years weighing at least 35 kg: one tablet daily, preferably taken with food.

The recommended dose of EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics for
reducing the risk of acquiring HIV is:

Adults: one tablet daily, preferably taken with food.

If you have difficulty swallowing, you may use the back of a spoon to crush the tablet. Then mix the powder in about 100 ml (half a glass) of water, orange juice, or grape juice and drink immediately.

Always take the dose prescribed by your doctor. This is important to ensure that your medicine is fully effective and to reduce the risk of developing resistance to treatment. Do not change the dose unless your doctor tells you to do so.
If you are being treated for HIV infection, your doctor will prescribe EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics together with other antiretroviral medicines. Refer to the package leaflet of the other antiretrovirals for guidance on how to take them.
If you are an adult taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to reduce the risk of acquiring HIV, take EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics every day, not only when you think you may have been exposed to HIV. Speak to your doctor if you have any questions about how to avoid acquiring HIV or prevent spreading HIV to others.

If you take more EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics than you should
If you accidentally take more EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics than the recommended dose, contact your doctor or the nearest emergency department immediately. Take the medicine container with you so that you can easily describe what you have taken.

If you miss a dose
It is important not to miss doses of EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics.

If you remember within 12 hours of your usual dosing time, take the missed tablet as soon as possible, preferably with food. Then take the next dose at the usual time.
If you remember 12 hours or more after your usual dosing time, do not take the missed dose. Wait and take the next dose at the usual time, preferably with food.

If you vomit within 1 hour of taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics, take another tablet. Do not take another tablet if you vomit more than 1 hour after taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics.

Do not stop taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics

If you are taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to treat HIV infection, stopping the tablets may reduce the effectiveness of the anti-HIV therapy prescribed by your doctor.
If you are taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics to reduce the risk of acquiring HIV, do not stop taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics or skip doses. If you stop taking EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics or miss doses, your risk of acquiring HIV may increase.

Do not stop treatment with EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics without first consulting your doctor.

If you have hepatitis B, it is especially important not to stop treatment with EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics without first talking to your doctor. Blood tests may need to be repeated for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended, as it may lead to worsening of hepatitis, which could be potentially life-threatening.

Contact your doctor immediately if you experience any new or unusual symptoms after stopping treatment, particularly symptoms typically associated with hepatitis B infection.

If you have any questions about how to use this medicine, consult your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everyone gets them.

Possible serious side effects:

Lactic acidosis (excess lactic acid in the blood), is a rare but potentially life-threatening side effect. Lactic acidosis occurs more frequently in women, especially if overweight, and in people with liver disease. The following may be signs of lactic acidosis:
- shortness of breath
- drowsiness
- nausea, vomiting
- stomach pain

If you think you have lactic acidosis, seek medical advice immediately.

Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weakened immune system), signs and symptoms of inflammation due to previous infections may occur shortly after starting anti-HIV treatment. These symptoms are believed to result from an improved immune response, allowing the body to fight infections that may have been present without obvious symptoms.
Autoimmune disorders, in which the immune system attacks healthy body tissue, may also occur after starting medicines to treat HIV infection. Autoimmune disorders may occur many months after starting treatment. Look out for symptoms of infection or other symptoms such as:
- muscle weakness
- weakness starting in the hands and feet and moving up towards the trunk
- palpitations, tremor, or hyperactivity

If you notice these or other symptoms of inflammation or infection, seek medical advice immediately.

Possible side effects:

Very common side effects
(may affect more than 1 in 10 people)

diarrhoea, vomiting, nausea
dizziness, headache
rash
feeling weak, muscle weakness

Blood tests may also show:

reduced phosphate levels in the blood
elevated creatine kinase

Common side effects
(may affect up to 1 in 10 people)

pain, stomach ache
difficulty sleeping, nightmares
digestive problems resulting from discomfort after meals, feeling of fullness, intestinal gas
skin rashes (including red spots or pustules, sometimes with blisters and skin swelling), which may be an allergic reaction, burning sensation, change in skin colour with appearance of dark patches
other allergic reactions such as shortness of breath, swelling, or feeling of light-headedness

Blood tests may also show:

decreased white blood cell count (this may make you more susceptible to infection)
increased triglycerides (fatty acids), bile, or glucose in the blood
problems with liver and pancreas

Uncommon side effects
(may affect up to 1 in 100 people)

abdominal pain caused by inflammation of the pancreas
swelling of the face, lips, tongue, or throat
anaemia (low red blood cell count)
muscle breakdown, muscle pain, or muscle weakness, which may occur due to damage to renal tubular cells

Blood tests may also show:

reduced potassium levels in the blood
increased creatinine in the blood
changes in urine

Rare side effects
(may affect up to 1 in 1,000 people)

lactic acidosis (see Possible serious side effects)
fatty liver
yellowing of the skin and eyes, itching, or abdominal pain caused by liver inflammation
kidney inflammation, excessive urination and thirst, kidney failure, damage to renal tubular cells
softening of the bones (with bone pain and sometimes fractures)
back pain caused by kidney problems

Damage to renal tubular cells may be associated with muscle breakdown, softening of the bones (with bone pain and sometimes fractures), muscle pain, muscle weakness, and decreased potassium or phosphate levels in the blood.

If you notice any of these side effects listed above, or if any of them become severe, consult your doctor or pharmacist.

The frequency of the following side effects is unknown.

Bone problems. Some patients taking combination antiretroviral medicines such as EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). Long-term use of this type of medicine, use of corticosteroids, alcohol consumption, a very weak immune system, and being overweight may be some of the many risk factors for developing this condition. Signs of osteonecrosis include:
- joint stiffness
- joint pain (especially in the hip, knee, and shoulder)
- difficulty moving

If you notice any of these symptoms, consult your doctor.

During treatment for HIV, an increase in weight and in blood lipid and glucose levels may occur. This is partly related to the recovery of health status and lifestyle, and in the case of blood lipids, sometimes to the HIV medicines themselves. Your doctor will monitor these changes.

Other effects in children

Children who have been given emtricitabine have very commonly experienced skin pigmentation changes, including the appearance of dark patches on the skin.
Children have commonly experienced low red blood cell count (anaemia), which may cause tiredness or shortness of breath in the child.

If you notice any of these symptoms, consult your doctor.

Reporting of side effects

If you experience any side effect, including those not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generici

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and the outer packaging after “Exp.”.
The expiry date refers to the last day of that month.
Store in the original packaging to protect the medicine from moisture. Keep the bottle tightly closed.
After first opening the bottle, use within 30 days and store below 25°C.
Do not dispose of any medicine via wastewater or household waste. Ask your pharmacist how to dispose of
medicines no longer required. This will help protect the environment.

6. Package contents and other information

What EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici contains

The active substances are emtricitabine and tenofovir. Each film-coated tablet of EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300.6 mg of tenofovir disoproxil succinate).
The other components are monohydrate lactose, microcrystalline cellulose (E460), pregelatinized maize starch, sodium croscarmellose, magnesium stearate (E470b), poly(vinyl alcohol) (E1203), titanium dioxide (E171), macrogol 4000 (E1521), talc (E553b), indigo carmine aluminium lake (E132).

Description of the appearance of EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici and contents of the pack
The film-coated tablets of EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici 200 mg/245 mg are blue, capsule-shaped, and smooth on both sides. The tablet dimensions are 19.3 mm x 8.8 mm ± 5%.
The film-coated tablets of EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici 200 mg/245 mg are available in HDPE bottles containing 30 tablets. Each bottle contains silica gel as a desiccant, which must remain in the bottle to protect the tablets. The silica gel is contained in a separate sachet and must not be swallowed.

Marketing Authorization Holder
DOC Generici S.r.l. – Via Turati 40 – 20121 Milano – Italy.

Manufacturer
Remedica Ltd - Aharnon Street, Limassol Industrial Estate, 3056 Limassol – Cyprus.

This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Netherlands: Emtricitabine/Tenofovir disoproxil DOC Generici, 200mg/245mg filmomhulde tabletten
Italy: EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici

EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici
SIDE 1
REMINDER CARD
If you have been prescribed EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici for pre-exposure prophylaxis, this has been done to reduce the risk of acquiring HIV-1 infection. For the medicine to be effective, it is important that you do not miss any dose. The recommended dose is one tablet of EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici daily. Take EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici exactly as prescribed by your doctor.
Whenever possible, EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici should be taken with food. It may be helpful to make taking EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici part of your daily routine, for example by taking it with lunch or when brushing your teeth after breakfast. It is important to find a time that suits you.
It may help to use a weekly pill dispenser, filling it with tablets each week.
You may also find it useful to use a calendar, marking off each day after taking EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici. Starting from your first week of treatment, mark the day you start EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici, and then mark the corresponding box each day after taking EMTRICITABINA E TENOFOVIR DISOPROXIL DOC Generici. You can also note the date when you took the first tablet from a new bottle. If you are unsure whether you took the tablet, you can count the number of tablets remaining in the bottle (each new bottle contains 30 tablets).

	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6

If you already use a calendar on your mobile phone or PC, you can add a reminder for your
EMTRICITABINE AND TENOFOVIR DISOPROXIL DOC Generics.
DATE OF TAKING THE FIRST TABLET OF EMTRICITABINE AND TENOFOVIR
DISOPROXIL DOC Generics FROM A NEW BOTTLE (DAY/MONTH/YEAR): ___/___/___
SIDE 2
APPOINTMENT REMINDER
Your next visit is:
Appointment
Date
Time
Place
Reporting of adverse reactions
If you experience any adverse reaction, including those not listed in this leaflet, please contact your
doctor or pharmacist. You can also report adverse reactions directly via the national reporting system at the following website: http://
http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa